My Resources
The information provided on this site is general education information and does not take the place of your healthcare professional’s advice. Please always follow your healthcare professional’s instructions and talk with him/her about any questions or problems you have regarding your health and treatment.
Patient Diaries
To find out more about KEYTRUDA® (pembrolizumab) including what to remember, possible side effects, what to look out for and a weekly treatment tracker, download the relevant patient diary below.
Endometrial Cancer Combination Diary
For patients receiving KEYTRUDA® (pembrolizumab) as a combination with LENVIMA® (lenvatinib).
GB-KLE-00193 | Date of Preparation: January 2024
Bladder Cancer
Further information
There is more to read about bladder cancer, and you can find out more information on the following websites:
Classic Hodgkin Lymphoma (cHL)
Further information
There is more information available about cHL on the following websites:
Colorectal Cancer (CRC)
Further information
There is more information available about colorectal cancer on the following websites:
Head and Neck Squamous Cell Carcinoma (HNSCC)
Further information
There is more information available about HNSCC on the following websites:
Kidney Cancer
Further information
There is more information available about kidney cancer on the following websites:
Melanoma
Further information
There is more information available about melanoma on the following websites:
Non-Small Cell Lung Cancer (NSCLC)
Further information
There is more information available about NSCLC on the following websites:
Oesophageal Cancer
Further information
There is more information available about oesophageal cancer on the following websites:
Triple-Negative Breast Cancer (TNBC)
Further information
There is more information available about triple-negative breast cancer on the following websites:
Supporting documentation
KEYTRUDA® (pembrolizumab)
Summary of Product Characteristics | Patient Information Leaflet
GB-PDO-03109 | Date of Preparation: June 2024
Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom.
Registered in England No. 233687 © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects, you can help provide more information on the safety of this medicine.